Logo image of IGMS

IGM BIOSCIENCES INC (IGMS) Stock Fundamental Analysis

NASDAQ:IGMS - Nasdaq - US4495851085 - Common Stock - Currency: USD

1.18  -0.06 (-4.84%)

After market: 1.18 0 (0%)

Fundamental Rating

3

Taking everything into account, IGMS scores 3 out of 10 in our fundamental rating. IGMS was compared to 561 industry peers in the Biotechnology industry. While IGMS seems to be doing ok healthwise, there are quite some concerns on its profitability. IGMS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IGMS has reported negative net income.
In the past year IGMS has reported a negative cash flow from operations.
In the past 5 years IGMS always reported negative net income.
In the past 5 years IGMS always reported negative operating cash flow.
IGMS Yearly Net Income VS EBIT VS OCF VS FCFIGMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of IGMS (-73.69%) is worse than 67.02% of its industry peers.
IGMS's Return On Equity of -406.45% is on the low side compared to the rest of the industry. IGMS is outperformed by 77.01% of its industry peers.
Industry RankSector Rank
ROA -73.69%
ROE -406.45%
ROIC N/A
ROA(3y)-58.31%
ROA(5y)-50.05%
ROE(3y)-201.55%
ROE(5y)-138.68%
ROIC(3y)N/A
ROIC(5y)N/A
IGMS Yearly ROA, ROE, ROICIGMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

IGMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IGMS Yearly Profit, Operating, Gross MarginsIGMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

6

2. Health

2.1 Basic Checks

IGMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IGMS has more shares outstanding
Compared to 5 years ago, IGMS has more shares outstanding
IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IGMS Yearly Shares OutstandingIGMS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
IGMS Yearly Total Debt VS Total AssetsIGMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -6.85, we must say that IGMS is in the distress zone and has some risk of bankruptcy.
IGMS's Altman-Z score of -6.85 is on the low side compared to the rest of the industry. IGMS is outperformed by 67.56% of its industry peers.
There is no outstanding debt for IGMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.85
ROIC/WACCN/A
WACC10.1%
IGMS Yearly LT Debt VS Equity VS FCFIGMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

A Current Ratio of 5.14 indicates that IGMS has no problem at all paying its short term obligations.
IGMS has a Current ratio of 5.14. This is comparable to the rest of the industry: IGMS outperforms 55.44% of its industry peers.
A Quick Ratio of 5.14 indicates that IGMS has no problem at all paying its short term obligations.
IGMS has a Quick ratio (5.14) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.14
Quick Ratio 5.14
IGMS Yearly Current Assets VS Current LiabilitesIGMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

IGMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.25%, which is quite impressive.
Looking at the last year, IGMS shows a very strong growth in Revenue. The Revenue has grown by 25.77%.
EPS 1Y (TTM)32.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.55%
Revenue 1Y (TTM)25.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0.4%

3.2 Future

IGMS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.78% yearly.
The Revenue is expected to grow by 33.27% on average over the next years. This is a very strong growth
EPS Next Y66.62%
EPS Next 2Y34.51%
EPS Next 3Y20.83%
EPS Next 5Y11.78%
Revenue Next Year122.54%
Revenue Next 2Y79.68%
Revenue Next 3Y61.2%
Revenue Next 5Y33.27%

3.3 Evolution

IGMS Yearly Revenue VS EstimatesIGMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M 15M
IGMS Yearly EPS VS EstimatesIGMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IGMS. In the last year negative earnings were reported.
Also next year IGMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGMS Price Earnings VS Forward Price EarningsIGMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IGMS Per share dataIGMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as IGMS's earnings are expected to grow with 20.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.51%
EPS Next 3Y20.83%

More info and screens

0

5. Dividend

5.1 Amount

IGMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IGM BIOSCIENCES INC

NASDAQ:IGMS (5/21/2025, 8:05:53 PM)

After market: 1.18 0 (0%)

1.18

-0.06 (-4.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners59.9%
Inst Owner Change-18.02%
Ins Owners4.57%
Ins Owner Change-0.11%
Market Cap70.54M
Analysts48.33
Price Target1.91 (61.86%)
Short Float %2.82%
Short Ratio4.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.4%
Min EPS beat(2)-23.77%
Max EPS beat(2)18.96%
EPS beat(4)2
Avg EPS beat(4)-488.19%
Min EPS beat(4)-1950.05%
Max EPS beat(4)18.96%
EPS beat(8)6
Avg EPS beat(8)-240.76%
EPS beat(12)9
Avg EPS beat(12)-161.84%
EPS beat(16)13
Avg EPS beat(16)-120.29%
Revenue beat(2)2
Avg Revenue beat(2)45.95%
Min Revenue beat(2)2.58%
Max Revenue beat(2)89.31%
Revenue beat(4)2
Avg Revenue beat(4)-10.42%
Min Revenue beat(4)-97.74%
Max Revenue beat(4)89.31%
Revenue beat(8)2
Avg Revenue beat(8)-25.4%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.94%
PT rev (3m)-62.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)25.45%
EPS NY rev (1m)-0.68%
EPS NY rev (3m)-1.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.57%
Revenue NY rev (1m)1.21%
Revenue NY rev (3m)-1.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.33
P/FCF N/A
P/OCF N/A
P/B 1.46
P/tB 1.46
EV/EBITDA N/A
EPS(TTM)-2.92
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.56
OCFYN/A
SpS0.04
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.69%
ROE -406.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.31%
ROA(5y)-50.05%
ROE(3y)-201.55%
ROE(5y)-138.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.22%
Cap/Sales 218.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.14
Quick Ratio 5.14
Altman-Z -6.85
F-Score4
WACC10.1%
ROIC/WACCN/A
Cap/Depr(3y)127.25%
Cap/Depr(5y)475.26%
Cap/Sales(3y)584.64%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.55%
EPS Next Y66.62%
EPS Next 2Y34.51%
EPS Next 3Y20.83%
EPS Next 5Y11.78%
Revenue 1Y (TTM)25.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0.4%
Revenue Next Year122.54%
Revenue Next 2Y79.68%
Revenue Next 3Y61.2%
Revenue Next 5Y33.27%
EBIT growth 1Y26.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.78%
EBIT Next 3Y22.7%
EBIT Next 5YN/A
FCF growth 1Y22.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.41%
OCF growth 3YN/A
OCF growth 5YN/A